Register
Login

Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 28th 2022

We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment.

Questions

  1. Could you give us a brief overview of the current approval status of CAR-T cell therapy? (00:15-02:21)
  2. At present, is CAR-T cell therapy worth the high direct and indirect costs? (02:21-04:45)
  3. How can we reduce the costs associated with CAR-T cell therapy? (04:45-08:12)
  4. What are the challenges associated with the availability and accessibility of CAR-T cell therapy? (08:12-09:55)
  5. How can we improve efficacy and safety outcomes with these therapies? (09:55-12:11)
  6. How do you see the use of CAR-T cell therapy evolving in the coming years? (12:11-14:50)

Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup